Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Hutchison China MediTech Limited is a biotechnology business based in the US. Hutchison China MediTech shares (HCM) are listed on the NASDAQ and all prices are listed in US Dollars. Hutchison China MediTech employs 853 staff and has a trailing 12-month revenue of around USD$209.5 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$14.74 - USD$37 |
---|---|
50-day moving average | USD$34.4232 |
200-day moving average | USD$32.3768 |
Wall St. target price | USD$39.6 |
PE ratio | 17.6909 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.66 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Hutchison China MediTech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Hutchison China MediTech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Hutchison China MediTech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Hutchison China MediTech shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Revenue TTM | USD$209.5 million |
---|---|
Gross profit TTM | USD$-93,452,000 |
Return on assets TTM | -18.68% |
Return on equity TTM | -29.31% |
Profit margin | -52.68% |
Book value | $2.49 |
Market capitalisation | USD$4.5 billion |
TTM: trailing 12 months
There are currently 831,246 Hutchison China MediTech shares held short by investors – that's known as Hutchison China MediTech's "short interest". This figure is 15.7% down from 985,637 last month.
There are a few different ways that this level of interest in shorting Hutchison China MediTech shares can be evaluated.
Hutchison China MediTech's "short interest ratio" (SIR) is the quantity of Hutchison China MediTech shares currently shorted divided by the average quantity of Hutchison China MediTech shares traded daily (recently around 225882.06521739). Hutchison China MediTech's SIR currently stands at 3.68. In other words for every 100,000 Hutchison China MediTech shares traded daily on the market, roughly 3680 shares are currently held short.
However Hutchison China MediTech's short interest can also be evaluated against the total number of Hutchison China MediTech shares, or, against the total number of tradable Hutchison China MediTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hutchison China MediTech's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Hutchison China MediTech shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Hutchison China MediTech shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hutchison China MediTech.
Find out more about how you can short Hutchison China MediTech stock.
We're not expecting Hutchison China MediTech to pay a dividend over the next 12 months.
Hutchison China MediTech's shares were split on 30 May 2019.
Over the last 12 months, Hutchison China MediTech's shares have ranged in value from as little as $14.74 up to $37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hutchison China MediTech's is 0.5915. This would suggest that Hutchison China MediTech's shares are less volatile than average (for this exchange).
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, and markets prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, an inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma; and HMPL-689 for the treatment of indolent non-Hodgkin's lymphoma. In addition, it engages in the development of HMPL-453, an inhibitor for the potential treatment of solid tumors; HMPL-306, a molecule dual-inhibitor of isocitrate dehydrogenase 1 and 2 for the treatment of hematological malignancies, gliomas, and solid tumors; and clinical-stage EGFR inhibitors, such as Epitinib and theliatinib. Hutchison China MediTech Limited has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of combining surufatinib and fruquintinib with BeiGenes anti-PD-1 antibody tislelizumab for the treatment of various solid tumor cancers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.